Literature DB >> 22529291

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.

Jan B Egan1, Chang-Xin Shi, Waibhav Tembe, Alexis Christoforides, Ahmet Kurdoglu, Shripad Sinari, Sumit Middha, Yan Asmann, Jessica Schmidt, Esteban Braggio, Jonathan J Keats, Rafael Fonseca, P Leif Bergsagel, David W Craig, John D Carpten, A Keith Stewart.   

Abstract

The longitudinal evolution of a myeloma genome from diagnosis to plasma cell leukemia has not previously been reported. We used whole-genome sequencing (WGS) on 4 purified tumor samples and patient germline DNA drawn over a 5-year period in a t(4;14) multiple myeloma patient. Tumor samples were acquired at diagnosis, first relapse, second relapse, and end-stage secondary plasma cell leukemia (sPCL). In addition to the t(4;14), all tumor time points also shared 10 common single-nucleotide variants (SNVs) on WGS comprising shared initiating events. Interestingly, we observed genomic sequence variants that waxed and waned with time in progressive tumors, suggesting the presence of multiple independent, yet related, clones at diagnosis that rose and fell in dominance. Five newly acquired SNVs, including truncating mutations of RB1 and ZKSCAN3, were observed only in the final sPCL sample suggesting leukemic transformation events. This longitudinal WGS characterization of the natural history of a high-risk myeloma patient demonstrated tumor heterogeneity at diagnosis with shifting dominance of tumor clones over time and has also identified potential mutations contributing to myelomagenesis as well as transformation from myeloma to overt extramedullary disease such as sPCL.

Entities:  

Mesh:

Year:  2012        PMID: 22529291      PMCID: PMC3412329          DOI: 10.1182/blood-2012-01-405977

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  35 in total

1.  Hypodiploidy is a major prognostic factor in multiple myeloma.

Authors:  N V Smadja; C Bastard; C Brigaudeau; D Leroux; C Fruchart
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

2.  Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.

Authors:  J Shaughnessy; A Gabrea; Y Qi; L Brents; F Zhan; E Tian; J Sawyer; B Barlogie; P L Bergsagel; M Kuehl
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

Review 3.  Multiple myeloma: evolving genetic events and host interactions.

Authors:  W Michael Kuehl; P Leif Bergsagel
Journal:  Nat Rev Cancer       Date:  2002-03       Impact factor: 60.716

4.  Clonal competition with alternating dominance in multiple myeloma.

Authors:  Jonathan J Keats; Marta Chesi; Jan B Egan; Victoria M Garbitt; Stephen E Palmer; Esteban Braggio; Scott Van Wier; Patrick R Blackburn; Angela S Baker; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John D Carpten; Michael Barrett; Rafael Fonseca; A Keith Stewart; P Leif Bergsagel
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

5.  Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias.

Authors:  P Corradini; G Inghirami; M Astolfi; M Ladetto; C Voena; P Ballerini; W Gu; K Nilsson; D M Knowles; M Boccadoro
Journal:  Leukemia       Date:  1994-05       Impact factor: 11.528

6.  Clinical and biologic implications of recurrent genomic aberrations in myeloma.

Authors:  Rafael Fonseca; Emily Blood; Montserrat Rue; David Harrington; Martin M Oken; Robert A Kyle; Gordon W Dewald; Brian Van Ness; Scott A Van Wier; Kimberly J Henderson; Richard J Bailey; Philip R Greipp
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

7.  Deletion of the retinoblastoma gene in multiple myeloma.

Authors:  D D Dao; J R Sawyer; J Epstein; R G Hoover; B Barlogie; G Tricot
Journal:  Leukemia       Date:  1994-08       Impact factor: 11.528

8.  High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells.

Authors:  N Juge-Morineau; M P Mellerin; S Francois; M J Rapp; J L Harousseau; M Amiot; R Bataille
Journal:  Br J Haematol       Date:  1995-11       Impact factor: 6.998

9.  Plasma cell leukemia: an evaluation of response to therapy.

Authors:  P Noel; R A Kyle
Journal:  Am J Med       Date:  1987-12       Impact factor: 4.965

10.  A novel gene, AF1q, fused to MLL in t(1;11) (q21;q23), is specifically expressed in leukemic and immature hematopoietic cells.

Authors:  W Tse; W Zhu; H S Chen; A Cohen
Journal:  Blood       Date:  1995-02-01       Impact factor: 22.113

View more
  156 in total

1.  Synchronous Thyroid Involvement in Plasma Cell Leukemia Masquerading as Hashimoto's Thyroiditis: Role of Ancillary Cytology Techniques in Diagnostic Workup.

Authors:  Ashwani Tandon; T Roshni Paul; Rekha Singh; A M V R Narendra
Journal:  Endocr Pathol       Date:  2015-12       Impact factor: 3.943

Review 2.  Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes.

Authors:  Birgit Knoechel; Jens G Lohr
Journal:  J Autoimmun       Date:  2013-07-21       Impact factor: 7.094

3.  Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies.

Authors:  David Avigan; Parameswaran Hari; Minoo Battiwalla; Michael R Bishop; Sergio A Giralt; Nancy M Hardy; Nicolaus Kröger; Alan S Wayne; Katharine C Hsu
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-07       Impact factor: 5.742

Review 4.  Leukaemia 'firsts' in cancer research and treatment.

Authors:  Mel Greaves
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

5.  Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials.

Authors:  Elisabet E Manasanch; Neha Korde; Sham Mailankody; Nishant Tageja; Manisha Bhutani; Mark Roschewski; Ola Landgren
Journal:  Haematologica       Date:  2014-12       Impact factor: 9.941

6.  Clonal evolution in myeloma: a narrow road to remission.

Authors:  Cornelius C Miething
Journal:  Haematologica       Date:  2019-07       Impact factor: 9.941

Review 7.  Sequencing of nontransplant treatments in multiple myeloma patients with active disease.

Authors:  Andrew J Yee; Noopur S Raje
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

8.  Discovery platform for inhibitors of IgH gene enhancer activity.

Authors:  Nathan G Dolloff
Journal:  Cancer Biol Ther       Date:  2018-11-27       Impact factor: 4.742

Review 9.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2012-12-05       Impact factor: 12.531

Review 10.  The Tao of myeloma.

Authors:  Lawrence H Boise; Jonathan L Kaufman; Nizar J Bahlis; Sagar Lonial; Kelvin P Lee
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.